Sonidegib (LDE225): Sonidegib is an inhibitor of Shh signaling pathway that selectively targets Smo, which is approved in the United States, European Union, Switzerland, and Australia for the treatment of basal cell carcinoma.[560] A phase Ib/II, open‐label study assessed the safety and efficacy of the oral combination of LDE225 and ruxolitinib in patients with myelofibrosis. This evidence concerns the gene SHH and basal cell carcinoma.